Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Naturland Holding Zrt's Price-to-Tangible-Book or its related term are showing as below:
BUD:NATURLAND'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 9.19 Med: 11.05 Max: 13.32
Current: 13.32
During the past 5 years, Naturland Holding Zrt's highest Price to Tangible Book Ratio was 13.32. The lowest was 9.19. And the median was 11.05.
BUD:NATURLAND's Price-to-Tangible-Book is ranked worse than 92.58% of 836
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs BUD:NATURLAND: 13.32
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Naturland Holding Zrt Price-to-Tangible-Book Related Terms
Naturland Holding Zrt Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Naturland Holding Zrt's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NATURLAND vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Naturland Holding Zrt (BUD:NATURLAND) has a Price-to-Tangible-Book of 13.32 as of Sep. 02, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Naturland Holding Zrt and its competitors. According to the industry distribution chart, Naturland Holding Zrt ranks #774 out of 836 companies in the Drug Manufacturers industry, placing it in the top 92.6%.
Is Naturland Holding Zrt's Price-to-Tangible-Book too high?
Naturland Holding Zrt's current Price-to-Tangible-Book is 13.32. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.31. Naturland Holding Zrt's value of 13.32 is 476.6% above this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #774 out of 836 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #774 out of 836 companies for Price-to-Tangible-Book. This places Naturland Holding Zrt in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.31. Naturland Holding Zrt's value of 13.32 is 476.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.31, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current Price-to-Tangible-Book of 13.32 is 476.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Naturland Holding Zrt and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current Price-to-Tangible-Book is 13.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,921.52, compared to a current price of Ft2,820.00 — trading 3.5% below its estimated fair value. The current Price-to-Tangible-Book is 13.32 and 476.6% above the Drug Manufacturers industry median of 2.31. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current Price-to-Tangible-Book is 13.32 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,820.00 is trading 3.5% below its estimated GF Value™ of Ft2,921.52.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
Price-to-Tangible-Book: 13.32
GF Value™: Ft2,921.52 vs. price of Ft2,820.00 (3.5% below fair value)
Industry Position: 476.6% above the Drug Manufacturers median (#774 of 836)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
